Abstract
To compare long-term virologic benefits of antiretroviral regimens in persons with advanced human immunodeficiency virus (HIV) disease, a randomized, open-label study was conducted of 517 subjects with no or limited previous experience with antiretroviral therapy. Subjects received lamivudine plus zidovudine and indinavir (indinavir group), efavirenz plus indinavir (efavirenz + indinavir group), or nelfinavir plus indinavir (nelfinavir + indinavir group) and were monitored for 2.1 years. Virologic failure was lower in the efavirenz + indinavir group (P = .04) and higher in the nelfinavir + indinavir group (P = .006), compared with that in the indinavir group. No difference in grade 3 or 4 adverse event rates in the efavirenz + indinavir group (P = .97) and a trend toward an increased rate in the nelfinavir + indinavir group (P = .07), compared with the indinavir group, were noted. A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 625-634 |
| Number of pages | 10 |
| Journal | Journal of Infectious Diseases |
| Volume | 188 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2003 |
Fingerprint
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Immunology
Cite this
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. / Fischl, Margaret A; Ribaudo, Heather J.; Collier, Ann C.; Erice, Alejo; Giuliano, Marina; Dehlinger, Marjorie; Eron, Joseph J.; Saag, Michael S.; Hammer, Scott M.; Vella, Stefano; Morse, Gene D.; Feinberg, Judith E.
In: Journal of Infectious Diseases, Vol. 188, No. 5, 01.09.2003, p. 625-634.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease
AU - Fischl, Margaret A
AU - Ribaudo, Heather J.
AU - Collier, Ann C.
AU - Erice, Alejo
AU - Giuliano, Marina
AU - Dehlinger, Marjorie
AU - Eron, Joseph J.
AU - Saag, Michael S.
AU - Hammer, Scott M.
AU - Vella, Stefano
AU - Morse, Gene D.
AU - Feinberg, Judith E.
PY - 2003/9/1
Y1 - 2003/9/1
N2 - To compare long-term virologic benefits of antiretroviral regimens in persons with advanced human immunodeficiency virus (HIV) disease, a randomized, open-label study was conducted of 517 subjects with no or limited previous experience with antiretroviral therapy. Subjects received lamivudine plus zidovudine and indinavir (indinavir group), efavirenz plus indinavir (efavirenz + indinavir group), or nelfinavir plus indinavir (nelfinavir + indinavir group) and were monitored for 2.1 years. Virologic failure was lower in the efavirenz + indinavir group (P = .04) and higher in the nelfinavir + indinavir group (P = .006), compared with that in the indinavir group. No difference in grade 3 or 4 adverse event rates in the efavirenz + indinavir group (P = .97) and a trend toward an increased rate in the nelfinavir + indinavir group (P = .07), compared with the indinavir group, were noted. A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity.
AB - To compare long-term virologic benefits of antiretroviral regimens in persons with advanced human immunodeficiency virus (HIV) disease, a randomized, open-label study was conducted of 517 subjects with no or limited previous experience with antiretroviral therapy. Subjects received lamivudine plus zidovudine and indinavir (indinavir group), efavirenz plus indinavir (efavirenz + indinavir group), or nelfinavir plus indinavir (nelfinavir + indinavir group) and were monitored for 2.1 years. Virologic failure was lower in the efavirenz + indinavir group (P = .04) and higher in the nelfinavir + indinavir group (P = .006), compared with that in the indinavir group. No difference in grade 3 or 4 adverse event rates in the efavirenz + indinavir group (P = .97) and a trend toward an increased rate in the nelfinavir + indinavir group (P = .07), compared with the indinavir group, were noted. A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity.
UR - http://www.scopus.com/inward/record.url?scp=0141612909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141612909&partnerID=8YFLogxK
U2 - 10.1086/377311
DO - 10.1086/377311
M3 - Article
C2 - 12934177
AN - SCOPUS:0141612909
VL - 188
SP - 625
EP - 634
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 5
ER -